Efficacy and safety of saxagliptin in combination with metformin as initial therapy in C hinese patients with type 2 diabetes: R esults from the START study, a multicentre, randomized, double‐blind, active‐controlled, phase 3 trial

Saxagliptin 5 mg plus metformin significantly improved glycaemic control compared with either monotherapy in treatment-naïve Chinese patients with type 2 diabetes, and was well tolerated.